AstraZeneca Historical Balance Sheet

AZN Stock

USD 67.62 0.42 0.63%

Trend analysis of AstraZeneca PLC ADR balance sheet accounts such as Short Long Term Debt Total of 30.1 B, Other Current Liabilities of 19.6 B or Total Current Liabilities of 32.1 B provides information on AstraZeneca PLC's total assets, liabilities, and equity, which is the actual value of AstraZeneca PLC ADR to its prevalent stockholders. By breaking down trends over time using AstraZeneca PLC balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Dot-com Bubble

Housing Crash

Credit Downgrade

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining AstraZeneca PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether AstraZeneca PLC ADR is a good buy for the upcoming year.

AstraZeneca PLC Inventory

5.7 Billion

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About AstraZeneca Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of AstraZeneca PLC ADR at a specified time, usually calculated after every quarter, six months, or one year. AstraZeneca PLC Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of AstraZeneca PLC and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which AstraZeneca currently owns. An asset can also be divided into two categories, current and non-current.

AstraZeneca PLC Balance Sheet Chart

At this time, AstraZeneca PLC's Retained Earnings are very stable compared to the past year. As of the 1st of December 2024, Accounts Payable is likely to grow to about 6.1 B, while Property Plant And Equipment Net is likely to drop about 6.8 B.

Total Assets Short Long Term Debt Total Total Current Liabilities Total Stockholder Equity Common Stock Shares Outstanding Long Term Debt

Add Fundamental

Total Assets

Total assets refers to the total amount of AstraZeneca PLC assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in AstraZeneca PLC ADR books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on AstraZeneca PLC balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of AstraZeneca PLC ADR are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Common Stock Shares Outstanding

The total number of shares of a company's common stock that are currently owned by all its shareholders.

Long Term Debt

Long-term debt is a debt that AstraZeneca PLC ADR has held for over one year. Long-term debt appears on AstraZeneca PLC ADR balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on AstraZeneca PLC ADR balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.

Most accounts from AstraZeneca PLC's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into AstraZeneca PLC ADR current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	30.8B	29.2B	28.6B	30.1B
Total Assets	105.4B	96.5B	101.1B	106.2B

Short Long Term Debt Total Total Assets

AstraZeneca PLC balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Inventory	Total Liab	Total Current Assets	Short Term Debt	Other Stockholder Equity	Capital Stock	Common Stock	Other Assets	Intangible Assets	Other Liab
Total Assets		0.94	0.85	0.95	0.9	0.83	0.85	-0.24	-0.25	0.33	0.99	-0.08	0.18	0.91	-0.36	0.85	0.84	0.96	0.69	0.83	0.93	0.74	0.74	0.91	0.96	0.43
Short Long Term Debt Total	0.94		0.72	0.88	0.77	0.84	0.97	-0.52	-0.36	0.09	0.97	-0.32	-0.08	0.78	-0.49	0.9	0.89	0.96	0.53	0.82	0.86	0.72	0.72	0.96	0.95	0.48
Other Current Liab	0.85	0.72		0.85	0.85	0.6	0.6	0.07	-0.27	0.43	0.8	0.09	0.34	0.82	-0.2	0.59	0.6	0.75	0.67	0.77	0.85	0.55	0.55	0.68	0.77	0.23
Total Current Liabilities	0.95	0.88	0.85		0.87	0.77	0.78	-0.18	-0.23	0.34	0.93	-0.05	0.22	0.91	-0.31	0.72	0.71	0.9	0.64	0.91	0.88	0.64	0.64	0.87	0.88	0.3
Total Stockholder Equity	0.9	0.77	0.85	0.87		0.63	0.65	-0.03	-0.37	0.41	0.85	0.0	0.31	0.84	-0.22	0.55	0.75	0.74	0.76	0.81	0.97	0.69	0.69	0.7	0.82	0.08
Property Plant And Equipment Net	0.83	0.84	0.6	0.77	0.63		0.76	-0.38	-0.21	0.37	0.83	-0.1	0.2	0.84	-0.26	0.85	0.75	0.88	0.75	0.61	0.66	0.88	0.88	0.88	0.8	0.57
Net Debt	0.85	0.97	0.6	0.78	0.65	0.76		-0.67	-0.4	-0.15	0.9	-0.44	-0.31	0.64	-0.53	0.86	0.86	0.89	0.34	0.78	0.79	0.65	0.65	0.91	0.9	0.48
Retained Earnings	-0.24	-0.52	0.07	-0.18	-0.03	-0.38	-0.67		0.51	0.56	-0.34	0.75	0.71	0.0	0.55	-0.45	-0.51	-0.36	0.15	-0.34	-0.21	-0.38	-0.38	-0.47	-0.37	-0.28
Accounts Payable	-0.25	-0.36	-0.27	-0.23	-0.37	-0.21	-0.4	0.51		0.16	-0.24	0.57	0.27	-0.05	0.36	-0.08	-0.51	-0.15	-0.19	-0.41	-0.37	-0.37	-0.37	-0.33	-0.23	0.29
Cash	0.33	0.09	0.43	0.34	0.41	0.37	-0.15	0.56	0.16		0.22	0.5	0.92	0.56	0.18	0.15	0.08	0.25	0.77	0.08	0.23	0.35	0.35	0.15	0.16	0.04
Non Current Assets Total	0.99	0.97	0.8	0.93	0.85	0.83	0.9	-0.34	-0.24	0.22		-0.16	0.05	0.86	-0.44	0.89	0.84	0.97	0.6	0.83	0.91	0.72	0.72	0.91	0.99	0.51
Non Currrent Assets Other	-0.08	-0.32	0.09	-0.05	0.0	-0.1	-0.44	0.75	0.57	0.5	-0.16		0.76	0.22	0.82	-0.19	-0.36	-0.14	0.29	-0.17	-0.11	-0.12	-0.12	-0.23	-0.2	-0.03
Cash And Short Term Investments	0.18	-0.08	0.34	0.22	0.31	0.2	-0.31	0.71	0.27	0.92	0.05	0.76		0.48	0.54	-0.03	-0.09	0.08	0.69	-0.01	0.11	0.18	0.18	0.01	-0.02	-0.11
Common Stock Shares Outstanding	0.91	0.78	0.82	0.91	0.84	0.84	0.64	0.0	-0.05	0.56	0.86	0.22	0.48		-0.06	0.71	0.6	0.86	0.82	0.76	0.81	0.75	0.75	0.77	0.82	0.38
Short Term Investments	-0.36	-0.49	-0.2	-0.31	-0.22	-0.26	-0.53	0.55	0.36	0.18	-0.44	0.82	0.54	-0.06		-0.44	-0.45	-0.42	0.1	-0.33	-0.32	-0.22	-0.22	-0.39	-0.47	-0.3
Non Current Liabilities Total	0.85	0.9	0.59	0.72	0.55	0.85	0.86	-0.45	-0.08	0.15	0.89	-0.19	-0.03	0.71	-0.44		0.8	0.95	0.46	0.55	0.65	0.65	0.65	0.88	0.9	0.79
Inventory	0.84	0.89	0.6	0.71	0.75	0.75	0.86	-0.51	-0.51	0.08	0.84	-0.36	-0.09	0.6	-0.45	0.8		0.82	0.56	0.61	0.79	0.71	0.71	0.88	0.83	0.35
Total Liab	0.96	0.96	0.75	0.9	0.74	0.88	0.89	-0.36	-0.15	0.25	0.97	-0.14	0.08	0.86	-0.42	0.95	0.82		0.58	0.76	0.81	0.69	0.69	0.95	0.96	0.62
Total Current Assets	0.69	0.53	0.67	0.64	0.76	0.75	0.34	0.15	-0.19	0.77	0.6	0.29	0.69	0.82	0.1	0.46	0.56	0.58		0.45	0.65	0.81	0.81	0.56	0.55	0.15
Short Term Debt	0.83	0.82	0.77	0.91	0.81	0.61	0.78	-0.34	-0.41	0.08	0.83	-0.17	-0.01	0.76	-0.33	0.55	0.61	0.76	0.45		0.86	0.58	0.58	0.75	0.8	0.13
Other Stockholder Equity	0.93	0.86	0.85	0.88	0.97	0.66	0.79	-0.21	-0.37	0.23	0.91	-0.11	0.11	0.81	-0.32	0.65	0.79	0.81	0.65	0.86		0.71	0.71	0.76	0.9	0.19
Capital Stock	0.74	0.72	0.55	0.64	0.69	0.88	0.65	-0.38	-0.37	0.35	0.72	-0.12	0.18	0.75	-0.22	0.65	0.71	0.69	0.81	0.58	0.71		1.0	0.68	0.72	0.38
Common Stock	0.74	0.72	0.55	0.64	0.69	0.88	0.65	-0.38	-0.37	0.35	0.72	-0.12	0.18	0.75	-0.22	0.65	0.71	0.69	0.81	0.58	0.71	1.0		0.68	0.72	0.38
Other Assets	0.91	0.96	0.68	0.87	0.7	0.88	0.91	-0.47	-0.33	0.15	0.91	-0.23	0.01	0.77	-0.39	0.88	0.88	0.95	0.56	0.75	0.76	0.68	0.68		0.88	0.47
Intangible Assets	0.96	0.95	0.77	0.88	0.82	0.8	0.9	-0.37	-0.23	0.16	0.99	-0.2	-0.02	0.82	-0.47	0.9	0.83	0.96	0.55	0.8	0.9	0.72	0.72	0.88		0.56
Other Liab	0.43	0.48	0.23	0.3	0.08	0.57	0.48	-0.28	0.29	0.04	0.51	-0.03	-0.11	0.38	-0.3	0.79	0.35	0.62	0.15	0.13	0.19	0.38	0.38	0.47	0.56

Click cells to compare fundamentals

AstraZeneca PLC Account Relationship Matchups

AstraZeneca PLC balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Short Long Term Debt Total	18.2B	20.4B	30.8B	29.2B	28.6B	30.1B
Other Current Liab	2.1B	12.8B	14.9B	16.2B	18.7B	19.6B
Total Current Liabilities	18.1B	20.3B	22.6B	26.3B	30.5B	32.1B
Total Stockholder Equity	13.1B	15.6B	39.3B	37.0B	39.1B	41.1B
Property Plant And Equipment Net	8.3B	8.9B	10.2B	9.4B	10.5B	6.8B
Net Debt	12.9B	12.5B	24.5B	23.1B	22.8B	23.9B
Retained Earnings	2.8B	5.3B	1.7B	(574M)	4.5B	8.5B
Accounts Payable	14.0B	2.4B	2.8B	2.6B	3.3B	6.1B
Cash	5.4B	7.8B	6.3B	6.2B	5.8B	4.7B
Non Current Assets Total	45.8B	47.2B	79.1B	73.9B	76.1B	79.9B
Non Currrent Assets Other	1.7B	1.1B	1.1B	1.1B	931M	1.4B
Cash And Short Term Investments	6.2B	8.0B	6.4B	6.4B	5.9B	5.8B
Common Stock Shares Outstanding	2.6B	2.6B	2.9B	3.1B	3.1B	2.9B
Liabilities And Stockholders Equity	61.4B	66.7B	105.4B	96.5B	101.1B	106.2B
Non Current Liabilities Total	28.7B	30.8B	43.5B	33.1B	31.4B	33.0B
Inventory	3.2B	4.0B	9.0B	4.7B	5.4B	5.7B
Total Liab	46.8B	51.1B	66.1B	59.4B	62.0B	65.1B
Total Current Assets	15.6B	19.5B	26.2B	22.6B	25.1B	15.3B
Short Term Debt	2.0B	2.4B	2.9B	6.5B	6.4B	6.7B
Other Stockholder Equity	8.4B	8.0B	35.1B	35.2B	35.2B	36.9B
Other Assets	3.5B	4.3B	5.3B	4.2B	4.8B	5.0B
Intangible Assets	20.8B	20.9B	42.4B	39.3B	38.1B	40.0B
Other Liab	10.3B	10.5B	13.0B	8.5B	9.8B	6.7B
Long Term Debt	15.7B	17.5B	28.1B	23.0B	22.4B	11.3B
Good Will	11.7B	11.8B	20.0B	19.8B	20.0B	21.1B
Other Current Assets	971M	1.9B	4.8B	4.4B	5.4B	5.3B
Property Plant Equipment	8.3B	8.9B	10.2B	9.4B	10.9B	7.9B
Current Deferred Revenue	28M	1.6B	1.0B	181M	149M	156.5M
Net Receivables	5.2B	5.7B	8.8B	9.9B	8.4B	4.5B
Property Plant And Equipment Gross	8.3B	8.9B	10.2B	9.4B	19.1B	20.1B
Accumulated Other Comprehensive Income	1.6B	1.6B	1.6B	1.6B	(949M)	(996.5M)
Noncontrolling Interest In Consolidated Entity	1.6B	1.5B	16M	21M	23M	21.9M
Additional Paid In Capital	8.1B	8.1B	35.3B	35.3B	35.3B	37.1B
Net Tangible Assets	(19.4B)	(17.2B)	(23.1B)	(22.1B)	(19.9B)	(20.9B)

Pair Trading with AstraZeneca PLC

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if AstraZeneca PLC position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in AstraZeneca PLC will appreciate offsetting losses from the drop in the long position's value.

Moving together with AstraZeneca Stock

0.78	HLN	Haleon plc	Pair Corr
0.9	JNJ	Johnson Johnson Sell-off Trend	Pair Corr
0.81	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.81	ANRO	Alto Neuroscience,	Pair Corr

Moving against AstraZeneca Stock

0.83	AXP	American Express Fiscal Year End 24th of January 2025	Pair Corr
0.78	FNMFO	Federal National Mortgage	Pair Corr
0.77	TRV	The Travelers Companies Fiscal Year End 17th of January 2025	Pair Corr
0.47	ITCL	Banco Ita Chile	Pair Corr
0.44	KB	KB Financial Group	Pair Corr

The ability to find closely correlated positions to AstraZeneca PLC could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace AstraZeneca PLC when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back AstraZeneca PLC - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling AstraZeneca PLC ADR to buy it.

The correlation of AstraZeneca PLC is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as AstraZeneca PLC moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if AstraZeneca PLC ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for AstraZeneca PLC can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock:

How To Invest In AstraZeneca

Details

Is AstraZeneca Stock a good investment?

Details

What is AstraZeneca PLC's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.034

Dividend Share

2.97

Earnings Share

2.08

Revenue Per Share

2.7424

Quarterly Revenue Growth

0.18

The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

AstraZeneca Historical Balance Sheet

AstraZeneca PLC Inventory

5.7 Billion

About AstraZeneca Balance Sheet Analysis

AstraZeneca PLC Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Common Stock Shares Outstanding

Long Term Debt

AstraZeneca PLC balance sheet Correlations

AstraZeneca PLC Account Relationship Matchups

High Positive Relationship

High Negative Relationship

AstraZeneca PLC balance sheet Accounts

Pair Trading with AstraZeneca PLC

Moving together with AstraZeneca Stock

Moving against AstraZeneca Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Common Stock	+ 1.0	Capital Stock
Non Current Assets Total	+ 0.99	Total Assets
Intangible Assets	+ 0.99	Non Current Assets Total
Net Debt	+ 0.97	Short Long Term Debt Total
Non Current Assets Total	+ 0.97	Short Long Term Debt Total
Other Stockholder Equity	+ 0.97	Total Stockholder Equity

Retained Earnings	- 0.67	Net Debt
Short Term Investments	- 0.53	Net Debt
Retained Earnings	- 0.52	Short Long Term Debt Total
Inventory	- 0.51	Accounts Payable
Inventory	- 0.51	Retained Earnings
Short Term Investments	- 0.49	Short Long Term Debt Total